ALX Oncology SVP sells shares for tax obligations

ALX Oncology Holdings Inc. senior vice president of finance and chief accounting officer Shelly Pinto reported a small open-market sale of common stock.

Accepted by SEC EDGAR 03/23/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. senior vice president of finance and chief accounting officer Shelly Pinto reported a small open-market sale of common stock. On March 19, 2026, she sold 903 shares at $2.17 per share. According to the footnote, the shares were sold to satisfy her tax obligations related to the vesting of performance-based restricted stock units, indicating a tax-driven, routine transaction rather than a discretionary portfolio move. After this sale, Pinto directly holds 86,805 shares of ALX Oncology common stock.

Insider Trade Summary

Net Seller: 903 shares

Net Sell 1 txn

Insider Pinto Shelly

Role SVP, FINANCE AND CAO

Sold 903 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	903	$2.17	$2K

Holdings After Transaction: Common Stock — 86,805 shares (Direct)

Footnotes (1)

1. F1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Shelly Pinto report for ALX Oncology (ALXO)?

Shelly Pinto, SVP Finance and CAO of ALX Oncology, reported an open-market sale of company common stock. She sold 903 shares on March 19, 2026, in a transaction disclosed on a Form 4 insider trading report.

How many ALX Oncology (ALXO) shares did Shelly Pinto sell and at what price?

Shelly Pinto sold 903 shares of ALX Oncology common stock at $2.17 per share. The transaction was reported as an open-market sale, providing specific detail on both the number of shares and the per-share sale price.

Why did Shelly Pinto sell ALX Oncology (ALXO) shares in this Form 4 filing?

The filing states the shares were sold to satisfy Shelly Pinto’s tax obligations tied to the vesting of performance-based restricted stock units. This indicates the sale was tax-related rather than a discretionary sale based on a change in investment view.

How many ALX Oncology (ALXO) shares does Shelly Pinto hold after the reported sale?

Following the reported sale, Shelly Pinto directly holds 86,805 shares of ALX Oncology common stock. This remaining position shows she continues to own a substantial number of shares after the relatively small, tax-related transaction.

Was Shelly Pinto’s ALX Oncology (ALXO) transaction a buy or sell action?

The Form 4 identifies the transaction as a sale, coded “S” for an open-market or private sale transaction. It reflects the disposition of 903 ALX Oncology common shares rather than an acquisition of additional shares.

Does Shelly Pinto’s ALX Oncology (ALXO) Form 4 filing indicate any option exercises?

No derivative exercises are listed in this Form 4. The transaction summary shows zero derivative exercises, and the derivative position section is empty, meaning the filing only reports a common stock sale related to tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinto Shelly

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE AND CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		S(1)		903	D	$2.17	86,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units.

	/s/ Shelly Pinto	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)